dr. shaw discusses efficacy of lorlatinib in alk nsclc
Published 6 years ago • 874 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
2:04
dr. shaw discusses lorlatinib in lung cancer
-
1:15
efficacy results for lorlatinib in patients with alk-positive nsclc
-
1:30
efficacy of lorlatinib in nsclc post-second generation alk tki
-
2:32
dr. shaw discusses ldk378 and alectinib (af802) for alk-positive nsclc
-
6:41
next-generation alk inhibitors for nsclc
-
1:57
dr. shaw on sequencing strategies in alk-positive nsclc
-
2:26
dr. shaw on alectinib as first-line therapy in lung cancer
-
1:17
dr. bazhenova on the potential approval of lorlatinib for patients with alk-positive nsclc
-
1:35
dr. shaw on the phase iii results of the alex trial in nsclc
-
1:28
dr. paik on the potential approval of lorlatinib for patients with alk-positive nsclc
-
1:38
dr. alice shaw describes ldk378 in alk-positive non-small cell lung cancer
-
4:49
emerging alk/ros1 tkis for nsclc
-
2:37
crown: lorlatinib in treatment-naïve patients with alk-positive advanced nsclc
-
1:42
dr. alice shaw compares crizotinib and chemotherapy in nsclc
-
1:52
dr. shaw on crizotinib versus chemotherapy in alk-positive nsclc
-
1:58
dr. shaw on crizotinib in alk-positive lung cancer
-
3:46
ifct-1803 lorlatu cohort: real-world evidence supporting lorlatinib in alk nsclc
-
6:14
lorlatinib as first-line treatment for alk-positive advanced lung cancer
-
1:21
dr. shaw on crizotinib resistance in alk-positive lung cancer